Program Leaders

点击翻译按钮获取中文摘要

The 3 new senior leaders, Dr. Gudkov, Dr. Adjei, and Mr. Walker, bring fresh ideas and perspectives to the Institute as well as a wealth of scientific program development, and administrative leadership experience garnered from their involvement at other major NCI-designated cancer programs (Case Comprehensive Cancer Center, Mayo Clinic Cancer Center and the Ohio State University Comprehensive Cancer Center, respectively). Each of the Senior Leaders also plays a pivotal role in a CCSG Programs or Shared Resources. Dr. Adjei serves as Leader of the Molecular Targets and Experimental Therapeutics (MTET) and oversees Clinical Research Services, Dr. Gudkov is Leader of the Cell Stress and Biophysical Therapies (CSBT) Program, and Dr. James Marshall leads the Cancer Prevention and Population Sciences (CPPS) program. Dr. Candace Johnson is an active participant in the Prostate Program and MTET, while Dr. Trump participates in the Molecular Targets and Experimental Therapeutics Program. Mr. Walker serves as the CCSG Administrator and oversees the CCSG shared resources. All members of the Senior Leadership Team are active in the faculty recruitment process, serving as chairs or members of search committees. Further they are also involved in coordinating the EAB meetings, annual retreats, symposia/seminar series and participating in development activities. Each of these leaders is also active in national cancer research forums and well integrated into leadership and committee positions in these external arenas (ASCO, AACR, AACI, NCCN, NCI [caBIG, IRGs, parent committees]) assuring their awareness of and participation in deliberations regarding important national topics in cancer research, care and education and guaranteeing RPCI awareness of and leadership in the national trends. The Senior Leadership team interacts informally on a daily basis and meets formally on a weekly basis in the primary administrative leadership forum known as the RPCI Executive Council. Chaired by Dr. Trump, the Executive Council is the major decision-making body of the Institute, responsible for the on-going oversight of the RPCI and addressing all functional issues raised by its members. In addition, the Senior Leadership participates on the CCSG Steering Committee, a committee that meets monthly and includes the research program leaders as well as leaders of important CCSG and Institute initiatives [e.g., Imaging Development, Health Disparities]. The CCSG Steering Committee, chaired by Dr. Trump, provides a venue for strategic planning, program evaluation, membership review and approval and review of existing and proposed shared resources. Although there are several other venues where the Senior Leadership participates, it is through these two committees that primary decision-making is accomplished. There has been dramatic growth in RPCI during the last funding cycle. Over this funding cycle (2002 to 2006) the Senior Leadership team worked together to recruit more than 100 cancer investigators and clinicians, increase NCI funding by 74%, increase accruals to therapeutic investigator-initiated clinical trials and increase in out patient volume by 42% over this time period. As the number of cancer-focused basic, translational, clinical and population investigators at the RPCI have grown, four new Shared Resources have been established to support the needs of the membership with three more now in development. It is anticipated that the current Senior Leadership team will continue this successful trajectory via developing and executing longterm vision and strategic planning for the Institute.